Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ476MR)

This product GTTS-WQ476MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.

Specifications
Product type	mRNA
Modified bases	Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_003005.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	6403
UniProt ID	P16109

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ476MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6909MR	IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	ENB-0040
GTTS-WQ6998MR	IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	F-627
GTTS-WQ6903MR	IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	ENB-0040
GTTS-WQ11563MR	IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	MG-A271
GTTS-WQ3268MR	IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	ART621
GTTS-WQ9219MR	IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	IMMU-106
GTTS-WQ1928MR	IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	AGN 150998
GTTS-WQ14650MR	IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	SC0001-SCX

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST